Immix Biopharma (IMMX) Projected to Post Earnings on Wednesday

Immix Biopharma (NASDAQ:IMMX) is anticipated to issue its Q1 2026 results after the market closes on Wednesday, June 3rd. Analysts expect Immix Biopharma to post earnings of ($0.2084) per share for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 7, 2026 at 7:00 AM ET.

Immix Biopharma (NASDAQ:IMMX) last posted its earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. On average, analysts expect Immix Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Immix Biopharma Price Performance

Immix Biopharma stock opened at $8.84 on Wednesday. The stock has a market capitalization of $480.98 million, a P/E ratio of -9.61 and a beta of 0.12. The firm’s 50-day moving average is $9.41 and its two-hundred day moving average is $7.20. Immix Biopharma has a 12-month low of $1.87 and a 12-month high of $11.61.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Morgan Stanley started coverage on shares of Immix Biopharma in a report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 price target on the stock. Citizens Jmp restated a “market outperform” rating and set a $23.00 price target on shares of Immix Biopharma in a research note on Friday, March 27th. HC Wainwright lifted their price objective on Immix Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Friday. Mizuho boosted their target price on Immix Biopharma from $14.00 to $15.00 and gave the stock an “outperform” rating in a report on Monday, March 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $19.50.

Institutional Trading of Immix Biopharma

Large investors have recently added to or reduced their stakes in the stock. Balyasny Asset Management L.P. purchased a new position in Immix Biopharma in the fourth quarter valued at about $67,000. Velan Capital Investment Management LP boosted its position in shares of Immix Biopharma by 40.0% in the third quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock worth $73,000 after buying an additional 10,000 shares during the period. Tocqueville Asset Management L.P. boosted its position in shares of Immix Biopharma by 37.4% in the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock worth $84,000 after buying an additional 10,950 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Immix Biopharma in the fourth quarter valued at about $112,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Immix Biopharma in the fourth quarter valued at about $116,000. 11.26% of the stock is currently owned by institutional investors and hedge funds.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.